When Ozempic and Wegovy supply shortages became severe in 2022–2023, compounding pharmacies began producing semaglutide preparations — often at significantly lower costs than branded products. The FDA placed semaglutide on its drug shortage list, which under federal law permits compounding pharmacies to compound copies of shortage drugs. At peak, an estimated 1–2 million Americans were using compounded semaglutide.
What Compounded Semaglutide Actually Is
Compounded semaglutide is typically semaglutide base (not the sodium salt form used in branded products), synthesized by pharmaceutical ingredient manufacturers and compounded into injectable preparations by FDA-registered pharmacies. The active molecule — the semaglutide peptide sequence — is identical to branded products. What differs are the excipients, the salt form, the buffer system, and the absence of the branded products' specific delivery systems.
Some compounded preparations add ingredients not in branded products — most notably B12 (cyanocobalamin or methylcobalamin). The clinical rationale for this addition is debated; the evidence for meaningful benefit is limited.
The FDA Regulatory Landscape (2025–2026)
In February 2025, the FDA removed semaglutide from its drug shortage list, triggering the end of the shortage exemption that permitted compounding. This initiated a complex regulatory process: telehealth companies and compounding pharmacies challenged the removal, arguing that shortage conditions persisted despite the official designation change.
As of 2026, the regulatory landscape remains in flux. Compounding of essentially equivalent semaglutide by outsourcing facilities (503B) is no longer permitted. Compounding by 503A pharmacies for specific patients with documented clinical need (e.g., patients requiring doses or dosage forms not available commercially) may still be permitted under physician supervision. The specific legal situation continues to evolve and varies by state.
Quality and Safety Considerations
The primary safety concern with compounded semaglutide is quality consistency. FDA-registered 503A and 503B compounding facilities are subject to inspection and must meet USP standards for sterility, potency, and stability. Non-registered sources — which proliferated during the shortage period — offer no such assurance. Patients using compounded semaglutide should verify that their pharmacy is an FDA-registered facility and can provide a Certificate of Analysis for their specific batch.
Clinical Equivalence
No head-to-head clinical trial has compared compounded semaglutide base to branded Ozempic/Wegovy in terms of weight loss efficacy or safety outcomes. The available data is observational and anecdotal — suggesting broadly equivalent efficacy in clinical practice, though without the evidentiary standard of a controlled trial. The absence of branded products' specific formulation and delivery technology introduces theoretical variables that have not been rigorously studied.